Using a synthetic peptide to help recover from radiation exposure effects on the gut

Thrombopoietin mimetic (TPOm) as a medical countermeasure for GI-ARS

NIH-funded research Albert Einstein College of Medicine · NIH-11017476

This study is testing a new treatment called TPOm that could help people recover from gut damage caused by radiation exposure, like in nuclear accidents, by boosting blood cell production and healing, and it's currently being tested in animals to see how well it works.

Quick facts

Grant typeU01 cooperative agreement
Study typeNIH-funded research
Funding institutionAlbert Einstein College of Medicine NIH-funded
Lab location1 site (Bronx, United States)
Project IDNIH-11017476 on NIH RePORTER

What this research studies

This research focuses on developing a synthetic peptide called TPOm that mimics the action of thrombopoietin, a protein that helps in the production of blood cells. The study aims to address the lack of effective treatments for gastrointestinal damage caused by acute radiation syndrome (ARS), which can occur due to nuclear accidents or terrorism. By administering TPOm after radiation exposure, the research investigates its potential to improve survival rates and promote healing in the gut and other affected organs. The approach involves preclinical testing in animal models to evaluate the peptide's effectiveness in regenerating blood cells and repairing intestinal damage.

Who could benefit from this research

Good fit: Ideal candidates for this research would include individuals who have been exposed to radiation, such as those involved in nuclear accidents or emergencies.

Not a fit: Patients who have not been exposed to radiation or do not have gastrointestinal complications related to radiation exposure may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could provide a new treatment option for patients suffering from gastrointestinal damage due to radiation exposure.

How similar studies have performed: While there are existing treatments for hematopoietic acute radiation syndrome, this approach targeting gastrointestinal recovery is novel and has not been extensively tested in clinical settings.

Where this research is happening

Bronx, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Acute Radiation Syndrome
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.